Document:

EX-4.12

 Exhibit 4.12 

FIRST AMENDMENT TO LOAN AGREEMENT 
 This
FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of March 28, 2022 (the “Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability
incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party) and BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number
10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT
INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”). 

RECITALS 

A.    Collateral Agent, Lenders, Borrower, Parent and the other Credit Parties thereunder have entered into that
certain Loan Agreement, dated as of March 23, 2021 (the “Loan Agreement”). 
 B.    The
Issuer desires to enter into royalty-based financing in respect of which it will receive investments of up to $50 million on substantially the terms set out in that certain draft royalty agreement (which has been provided to the Collateral
Agent) by and between the Issuer, USB Focus Fund LumiraDx 2A, LLC, USB Focus Fund LumiraDx 2B, LLC and Pear Tree Partners, L.P., pursuant to which, inter alia, the Issuer will obtain such investments in order to finance new instruments in exchange
for which the Issuer will agree, inter alia, to make certain royalty payments to USB Focus Fund LumiraDx 2A, LLC and USB Focus Fund LumiraDx 2B, LLC (the “Royalty-Based Financing”). 

C.    Since the parties hereto do not concur as to whether the Royalty-Based Financing constitutes Indebtedness,
they have agreed to enter into this Amendment to, inter alia, confirm that the Royalty-Based Financing is permitted under the Loan Agreement. 

D.    In accordance with Section 11.5 of the Loan Agreement, Borrower (acting for its own behalf and on behalf
of the other Credit Parties), Collateral Agent and Lenders desire to amend the Loan Agreement to, among other things, reflect the above, on the terms and conditions set forth herein. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the
receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 

1.    Definitions. All capitalized terms used in this Amendment (including in the recitals hereof) and not
otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. The rules of interpretation set forth in the first paragraph of Section 13.1 of the Loan Agreement shall be applicable to this Amendment and are
incorporated herein by this reference. 
 2.    Amendments to Loan Agreement. 

a.    Subject only to the Issuer entering into the Royalty-Based Financing in accordance with clause
(c) of the definition of Permitted Indebtedness in Section 13.1 of the Loan Agreement (as amended hereby), the Loan Agreement shall be amended by deleting in its entirety clause (c) of the definition of Permitted Indebtedness in
Section 13.1 of the Loan Agreement and replacing it as follows: 

 “(c)    Indebtedness of Issuer or any other Credit
Party in connection with investments made available to the Issuer or such other Credit Party in a maximum amount of no more than $50,000,000 in the aggregate outstanding at any time; provided, that: (i) such Indebtedness shall be
unsecured; (ii) no Subsidiary shall guarantee the obligations of Issuer or such other Credit Party in respect of such Indebtedness; and (iii) the terms and conditions of such Indebtedness (A) shall be in all material respects as set
out in that certain draft royalty agreement by and between the Issuer, USB Focus Fund LumiraDx 2A, LLC, USB Focus Fund LumiraDx 2B, LLC and Pear Tree Partners, L.P., made available to the Collateral Agent and Lenders and attached as Exhibit A
hereto (the “Royalty Agreement”), or (B) shall not otherwise include (1) covenants (including financial covenants) and agreements that, taken as a whole, are more restrictive or onerous on the Issuer or such other Credit
Party in any material respect than the comparable covenants and agreements, taken as a whole, in the Loan Documents (as reasonably determined by a Responsible Officer of Issuer or such other Credit Party in good faith) or (2) any other
principal terms and conditions that, taken as a whole, are more restrictive or onerous on the Issuer or such other Credit Party in any material respect than the comparable covenants and agreements, taken as a whole, in the Royalty Agreement (as
reasonably determined by a Responsible Officer of Issuer or such other Credit Party in good faith).” 

b.    Subject only to the Issuer entering into the Royalty-Based Financing in accordance with clause
(c) of the definition of Permitted Indebtedness in Section 13.1 of the Loan Agreement (as amended hereby), the Loan Agreement shall be amended by deleting in its entirety clause (q) of the definition of Permitted Liens in
Section 13.1 of the Loan Agreement and replacing it as follows: 
 “(q)    [Reserved.]”

 c.    The Loan Agreement shall be amended by deleting in its entirety the definition of
Indebtedness in Section 13.1 of the Loan Agreement and replacing it as follows: 
 ““Indebtedness”
means, with respect to any Person, without duplication: (a) all indebtedness for advanced or borrowed money of, or credit extended to, such Person; (b) all obligations issued, undertaken or assumed by such Person as the deferred purchase
price of assets, properties, services or rights (other than (i) accrued expenses and trade payables entered into in the ordinary course of business which are not more than one hundred and eighty (180) days past due or subject to a bona
fide dispute, (ii) obligations to pay for services provided by employees and individual independent contractors in the ordinary course of business which are not more than one hundred and twenty (120) days past due or subject to a bona fide
dispute, (iii) liabilities associated with customer prepayments and deposits, and (iv) prepaid or deferred revenue arising in the ordinary course of business), including (A) any obligation or liability to pay deferred purchase price
or other similar deferred consideration for such assets, properties, services or rights where such deferred purchase price or consideration becomes due and payable solely upon the passage of time, and (B) any obligation described in clause
(b) of the definition of “Contingent Obligation” that is due and payable (or that becomes due and payable) solely with the passage of time (and not upon the occurrence of an event or the performance of an act); (c) the face
amount of all letters of credit issued for the account of such Person and, without duplication, all drafts drawn thereunder and all reimbursement or payment obligations with respect to letters of credit, surety bonds, performance bonds and other
similar instruments issued by such Person; (d) all obligations of such Person evidenced by notes, bonds, debentures or other debt securities or similar instruments (including debt securities convertible into Equity Interests), including
obligations so evidenced incurred in connection with the acquisition of properties, assets or businesses; (e) all indebtedness of such Person created or arising under any conditional sale or other title retention agreement or incurred

  
 2 

 
as financing, in either case with respect to property acquired by such Person (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited
to repossession or sale of such property); (f) all Capital Lease Obligations of such Person; (g) the principal balance outstanding under any synthetic lease, off-balance sheet loan or similar off balance
sheet financing product by such Person; (h) Disqualified Equity Interests; (i) all indebtedness referred to in clauses (a) through (g) above of other Persons secured by (or for which the holder of such indebtedness has
an existing right, contingent or otherwise, to be secured by) any Lien upon or in assets or properties (including accounts and contracts rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such
indebtedness of such other Persons; and (i) all Contingent Obligations of such Person described in clause (a) of the definition thereof.” 

d.    The Loan Agreement shall be amended by deleting in their entirety the Collateral Agent’s
notice details in Section 9 of the Loan Agreement and replacing it as follows: 
 “BioPharma Credit PLC 

c/o Beaufort House 
 51 New North
Road 
 Exeter EX4 4EP 
 United
Kingdom 
 Attn: Company Secretary 

Tel: +44 01 392 477 500 
 Fax: +44
01 392 498 288 
 Email: biopharmacreditplc@linkgroup.co.uk” 

e.    The Loan Agreement shall be amended by deleting in its entirety the facsimile number for
BioPharma Limited Partnership in Exhibit D of the Loan Agreement and replacing it as follows: 
 “Fax: +44 01 392 498
288” 
 3.    Representations and Warranties; Reaffirmation; Covenant to Deliver. 

a.    The Borrower hereby represents and warrants to each Lender and the Collateral Agent as
follows: 
  

	 	i.	 The Borrower has all requisite power and authority to enter into this Amendment and to carry out the
transactions contemplated hereby. 

  

	 	ii.	 This Amendment has been duly executed and delivered by the Borrower and, subject to the Legal Reservations, is
the legally valid and binding obligation of such Person, enforceable against such Person in accordance with its respective terms. 

  

	 	iii.	 The execution, delivery and performance by the Borrower of this Amendment have been duly authorized and do not
and will not: (A) contravene the terms of such Person’s Operating Documents; (B) violate any Requirements of Law, except to the extent that such violation could not, individually or in the aggregate, reasonably be expected to result
in a Material Adverse Change; (C) conflict with or result in any breach or contravention of, or require any payment to be made under any provision of any security issued by such Person or of any agreement, instrument

  
 3 

	 	
or other undertaking to which such Person is a party or affecting such Person or the assets or properties of such Person or any of its Subsidiaries or any order, writ, judgment, injunction,
decree, determination or award of any Governmental Authority by which such Person or any of its properties or assets are subject, except to the extent that such conflict, breach, contravention or payment could not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Change; (D) require any Governmental Approval, or other action by, or notice to, or filing with, any Governmental Authority (except such Governmental Approvals or other actions, notices and
filings which have been duly obtained, taken, given or made on or before the Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of
which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (E) require any approval, consent, exemption or authorization, or other action by, or notice to, or filing with,
any Person other than a Governmental Authority, including such Person’s stockholders, members or partners, (except such approvals, consents, exemptions, authorizations, actions, notices and filings which have been or will be duly obtained,
taken, given or made on or before the Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; or (F) constitute a material breach of or a material default under (which such default has not been cured or waived) or an event of default (or the
equivalent thereof, however described) under, or could reasonably be expected to give rise to the cancellation, termination or invalidation of or the acceleration of such Person’s or any Subsidiary’s obligations under, any Material
Contract. 

 b.    The Borrower hereby ratifies, confirms, reaffirms, and
acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, the
Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment. 

c.    The Borrower hereby agrees to deliver to the Collateral Agent a copy of the fully executed
Royalty Agreement or any such other agreement, pursuant to which Issuer or any other Credit Party enters into royalty-based financing constituting Indebtedness described in clause (c) of the definition of Permitted Indebtedness in
Section 13.1 of the Loan Agreement (as amended hereby) and copies of any material amendments, restatements, supplements or modifications thereto or thereof, in each case as promptly as reasonably practicable following the execution and delivery
thereof by all parties thereto, and, in connection therewith, the Collateral Agent hereby agrees to and acknowledges the provisions of Clause 8.3 of the Royalty Agreement (and any equivalent provision in any other royalty-based financing
constituting Indebtedness described in clause (c) of the definition of Permitted Indebtedness in Section 13.1 of the Loan Agreement (as amended hereby)). 

4.    References to and Effect on Loan Agreement. Except as specifically set forth herein, this Amendment
shall not modify or in any way affect any of the provisions of the Loan Agreement, which shall remain in full force and effect and is hereby ratified and confirmed in all respects. On and after the Effective Date, all references in the Loan
Agreement to “this Agreement,” “hereto,” “hereof,” “hereunder,” or words of like import shall mean the Loan Agreement as amended by this Amendment. 

  
 4 

 5.    Successors and Assigns. This Amendment binds and is
for the benefit of Borrower, the other Credit Parties, Lenders and the Collateral Agent and their respective successors and permitted assigns. 

6.    Governing Law; Venue; Jury Trial Waiver.    This Amendment shall be construed in
accordance with and governed by the law of the State of New York. The provisions of Section 10 (Choice of law, Venue and Jury Trial Waiver Etc.) of the Loan Agreement shall apply hereto as if more fully set forth herein as if references
therein to “this Agreement” were references to this Amendment. 
 7.    Counterparts. This
Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed
counterpart of this Amendment electronically or by facsimile shall be effective as delivery of an original executed counterpart of this Amendment. 

[Remainder of Page Intentionally Left Blank] 

  
 5 

 IN WITNESS WHEREOF, the undersigned hereto have caused this Amendment to be executed
as of the date first written above by each of their officers thereunto duly authorized. 
  

			
	 LUMIRADX INVESTMENT LIMITED,

as Borrower and a Credit Party on its own behalf and on behalf of each other Credit Party

		
	By	 	 /s/ Veronique Ameye

	Name:	 	Veronique Ameye
	Title:	 	Director

 [Signature page to First Amendment to Loan Agreement] 

			
	 BIOPHARMA CREDIT PLC,

as Collateral Agent

			
		
	By:	 	 Pharmakon Advisors, LP,

    its Investment Manager

			
		
	          	 	 By: Pharmakon Management I, LLC,
 its
General Partner

			
		
	By	 	 /s/ Pedro Gonzalez de Cosio

	Name:	 	Pedro Gonzalez de Cosio
	Title:	 	Managing Member
	
	 BPCR LIMITED PARTNERSHIP,

as a Lender

			
		
	By:	 	 Pharmakon Advisors, LP,

    its Investment Manager

			
		
	          	 	 By: Pharmakon Management I, LLC,
 its
General Partner

			
		
	By	 	 /s/ Pedro Gonzalez de Cosio

	Name:	 	Pedro Gonzalez de Cosio
	Title:	 	Managing Member
	
	 BIOPHARMA CREDIT INVESTMENTS V

(MASTER) LP, as Lender

			
		
	By:	 	BioPharma Credit Investments V GP LLC,
		 	    its general partner

			
		
	          	 	 By: Pharmakon Advisors, LP,
 its
Investment Manager

			
		
	By	 	 /s/ Pedro Gonzalez de Cosio

	Name:	 	Pedro Gonzalez de Cosio
	Title:	 	CEO and Managing Member

 [Signature page to First Amendment to Loan Agreement]EX-4.14

 Exhibit 4.14 

THIRD AMENDMENT TO LOAN AGREEMENT 
 This
THIRD AMENDMENT TO LOAN AGREEMENT (this “Third Amendment”), dated and effective as of July 18, 2022 (the “Third Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company
with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales
with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (“BPCR”) and BIOPHARMA
CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (“BioPharma Credit” and together with BPCR, the “Lenders” and each
a “Lender”). 
 RECITALS 

A. The Collateral Agent, the Lenders, the Borrower, the Parent and the other Credit Parties thereunder have entered into that certain Loan
Agreement, dated as of March 23, 2021 (as amended pursuant to the First Amendment to Loan Agreement dated March 28, 2022, the Second Amendment to Loan Agreement dated June 17, 2022 and as further amended from time to time, the
“Loan Agreement”). 
 B. In accordance with Section 11.5 (Amendments in writing; integration) of the Loan
Agreement, the Borrower (acting for its own behalf and on behalf of the other Credit Parties), the Collateral Agent and the Lenders desire to make an amendment to the definition of “Qualifying Financing” in Section 13.1 of the Loan
Agreement on the terms and conditions set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is
hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 
 1. Definitions. All capitalized
terms used in this Third Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. The rules of interpretation set forth in the first paragraph of Section 13.1
of the Loan Agreement shall be applicable to this Third Amendment and are incorporated herein by this reference. 
 2. Amendment to Loan
Agreement. 
 With effect from the date hereof, the Loan Agreement shall be amended by deleting the definition of
“Qualifying Financing” in Section 13.1 of the Loan Agreement in its entirety and replacing it as follows: 

““Qualifying Financing” means the Issuer raising, following the Amendment Effective Date, gross proceeds in an aggregate
amount equal to or greater than $100,000,000 (or its equivalent in another currency or currencies) through the issue of Qualifying Equity Interests.””. 

 3. Representations and Warranties; Reaffirmation; Covenant to Deliver. 

a. The Borrower hereby represents and warrants to each Lender and the Collateral Agent as follows: 

 

	 	i.	 The Borrower has all requisite power and authority to enter into this Third Amendment and to carry out the
transactions contemplated hereby. 

  

	 	ii.	 This Third Amendment has been duly executed and delivered by the Borrower and, subject to the Legal
Reservations, is the legally valid and binding obligation of such Person, enforceable against such Person in accordance with its respective terms. 

  

	 	iii.	 The execution, delivery and performance by the Borrower of this Third Amendment have been duly authorized and
do not and will not: (A) contravene the terms of such Person’s Operating Documents; (B) violate any Requirements of Law, except to the extent that such violation could not, individually or in the aggregate, reasonably be expected to
result in a Material Adverse Change; (C) conflict with or result in any breach or contravention of, or require any payment to be made under any provision of any security issued by such Person or of any agreement, instrument or other undertaking
to which such Person is a party or affecting such Person or the assets or properties of such Person or any of its Subsidiaries or any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which such
Person or any of its properties or assets are subject, except to the extent that such conflict, breach, contravention or payment could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change;
(D) require any Governmental Approval, or other action by, or notice to, or filing with, any Governmental Authority (except such Governmental Approvals or other actions, notices and filings which have been duly obtained, taken, given or made on
or before the Third Amendment Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or
in the aggregate, reasonably be expected to result in a Material Adverse Change; (E) require any approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Person other than a Governmental Authority,
including such Person’s stockholders, members or partners, (except such approvals, consents, exemptions, authorizations, actions, notices and filings which have been or will be duly obtained, taken, given or made on or before the Third
Amendment Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Change; or (F) constitute a material breach of or a material default under (which such default has not been cured or waived) or an event of default (or the equivalent thereof, however
described) under, or could reasonably be expected to give rise to the cancellation, termination or invalidation of or the acceleration of such Person’s or any Subsidiary’s obligations under, any Material Contract. 

 b. The Borrower hereby ratifies, confirms, reaffirms, and
acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Third Amendment, except as expressly provided herein. By executing this Third
Amendment, the Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Third Amendment. 

4. References to and Effect on Loan Agreement. Except as specifically set forth herein, this Third Amendment shall not modify or
in any way affect any of the provisions of the Loan Agreement, which shall remain in full force and effect and are hereby ratified and confirmed in all respects. On and after the Third Amendment Effective Date, all references in the Loan Agreement
to “this Agreement,” “hereto,” “hereof,” “hereunder,” or words of like import shall mean the Loan Agreement as amended by this Third Amendment. 

5. Successors and Assigns. This Third Amendment binds and is for the benefit of Borrower, the other Credit Parties, Issuer,
Lenders and the Collateral Agent and their respective successors and permitted assigns. 
 6. Governing Law; Venue; Jury Trial
Waiver. This Third Amendment shall be construed in accordance with and governed by the law of the State of New York. The provisions of Section 10 (Choice of law, Venue and Jury Trial Waiver Etc.) of the Loan Agreement shall apply
hereto as if more fully set forth herein as if references therein to “this Agreement” were references to this Third Amendment. 

7. Counterparts. This Third Amendment may be executed in any number of counterparts and by different parties on separate
counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Third Amendment. Delivery of an executed counterpart of this Third Amendment electronically or by facsimile shall be effective as
delivery of an original executed counterpart of this Third Amendment. 
 [Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the undersigned hereto have caused this Third Amendment to be
executed as of the date first written above by each of their officers thereunto duly authorized. 
  

			
	 LUMIRADX INVESTMENT LIMITED,

	 as Borrower and a Credit Party on its own behalf

and on behalf of each other Credit Party

		
	By	 	 /s/ Dorian LeBlanc

	Name:	 	Dorian LeBlanc
	Title:	 	Chief Financial Officer

			
	 BIOPHARMA CREDIT PLC, as Collateral Agent

	
	 By: Pharmakon Advisors, LP,

its Investment Manager

	
	 By: Pharmakon Management I, LLC, its General Partner

		
	 By
	 	 /s/ Pedro Gonzalez de Cosio

	 Name:
	 	 Pedro Gonzalez de Cosio

	 Title:
	 	 Managing Member

			
	 BPCR LIMITED PARTNERSHIP, as Lender

	
	 By: Pharmakon Advisors, LP,

its Investment Manager

	
	 By: Pharmakon Management I, LLC,

		
	 By
	 	 /s/ Pedro Gonzalez de Cosio

	 Name:
	 	 Pedro Gonzalez de Cosio

	 Title:
	 	 Managing Member

	
	 BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, as Lender

	
	 By: BioPharma Credit Investments V GP LLC,

its general partner

	
	 By: Pharmakon Advisors, LP, its Investment Manager

		
	 By
	 	 /s/ Pedro Gonzalez de Cosio

	 Name:
	 	 Pedro Gonzalez de Cosio

	 Title:
	 	 CEO and Managing Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]